Business Wire

CSC Finds Majority of World’s Largest Companies Susceptible to Phishing and Brand Abuse Due to Improper Domain Security

Share

CSC, a world leader in business, legal, tax, and domain security, today released its annual Domain Security Report: Forbes Global 2000 Companies , which found that despite the shift to modernize business environments and operations among the Global 2000 companies, web domains remain dangerously under protected.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005027/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Key findings from the 2021 Domain Security Report (Graphic: Business Wire)

CSC’s research also shows that most Global 2000 companies continue to lag in the adoption of domain security measures. Most notably, 81% of companies are not using registry locks. Other concerning findings illustrate that domain security remains an afterthought for many brands:

  • 70% of homoglyph (fuzzy match) domains—a tactic commonly used in phishing and brand abuse—are owned by third parties
  • 57% of the Global 2000 are relying on off-the-shelf consumer-grade registrars who offer limited domain security mechanisms to protect against domain and DNS hijacking

“Basic domain security measures continue to get overlooked because they’re still not considered an essential component to a company’s broader phishing, business email compromise, or ransomware mitigation approach,” said Mark Calandra, president of CSC Digital Brand Services. “A focus on securing legitimate domains while monitoring for malicious domains in parallel needs to be a bigger priority for companies to stay protected and thwart cyber risk. Otherwise, companies are exposing themselves to significant threats to their cyber security posture, data protection, intellectual property, supply chains, consumer safety, revenue, and reputation.”

CSC’s additional findings leave little doubt that bad actors are applying tactics to hide their tracks and accelerate their attempts to execute their attacks. The research found that among the 70% of third-party domains deemed suspicious:

  • 77% used domain privacy services or also had WHOIS details redacted
  • 43% are configured with MX email records, giving them the ability to send phishing emails
  • 56% were pointing to advertising, pay-per-click content, or being used for domain parking
  • 38% had inactive web content
  • 6% were pointing to brand impersonation and malicious content including phishing and potential malware delivery

The rise of cyber crime and digital fraud, along with a steady increase in domain registrations over the last 18 months, necessitates more industry oversight. At the same time, it’s imperative that companies get proactive with their domain security moving forward. Including security measures can help mitigate phishing—a common starting point in most ransomware attacks. Companies need to take a more aggressive cyber security approach to disrupt criminal activities taking place across their domain ecosystem.

Download the report now at cscdbs.com/securityreport .

To learn more about CSC’s approach to domain security, visit cscdbs.com.

About CSC

CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® for enterprise domain names, domain name system, and digital certificate management, as well as digital brand, fraud, and phishing protection. We secure companies against cyber threats to their online assets using our proprietary security solutions, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties. We also provide a combination of online brand monitoring and enforcement, taking a holistic approach to digital asset protection. Learn more about our domain management, security, brand protection, and fraud protection services at cscdbs.com.

Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Steve Bosk
W2 Communications
215-378-1056
CSC@w2comm.com
CSC Newsroom

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye